Chimeric Therapeutics (ASX: CHM) has received ethics approval for the initiation of a multi-site Phase 1/2 clinical trial of CHM CDH17 in patients with
March 11, 2024 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today's roundup of stocks to watch ...
Chimeric Therapeutics (ASX:CHM) has treated the first patient in its Advent-AML phase 1B clinical trial at The University of Texas MD Anderson Cancer Center.
Chimeric Therapeutics (ASX:CHM) has announced it will conduct an equity raising through a two-for-three entitlement offer of new shares, with the goal of raising up to $10 million.
Chimeric Therapeutics (ASX:CHM) has treated the third patient participating in its phase 1A dose escalation study at the City of Hope Hospital in California.
Sydney, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered...
Sydney, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered...
Sydney, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered...
Sydney, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered...
Sydney, June 24, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered...